Literature DB >> 15876807

Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy.

Kan Zen1, Hidekazu Irie, Tomoki Doue, Michitaka Takamiya, Tetsuhiro Yamano, Takahisa Sawada, Akihiro Azuma, Hiroaki Matsubara.   

Abstract

We examined the plasma levels of soluble Fas (sFas) or Fas ligand (sFas-L), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in patients with idiopathic nonobstructive (HNCM) and dilated-phase (DHCM) hypertrophic cardiomyopathy. Patients with idiopathic hypertrophic cardiomyopathy (HCM) may deteriorate to DHCM and the pathogenesis is unknown. The levels of these plasma cytokines were measured by ELISA and echocardiography was performed in 38 HNCM and 11 DHCM patients, and 10 normal subjects. The follow-up period was three years. In HNCM, TNF-alpha (43.3 +/- 45.2 versus 16.9 +/- 4.3 pg/mL) and IL-6 (65.1 +/- 86.4 versus 4.0 +/- 2.1 pg/mL) were slightly higher compared to normal subjects and sFas (3.7 +/- 1.2 versus 2.1 +/- 0.7 ng/mL) increased significantly. sFas (3.9 +/- 1.8), TNF-alpha (79.3 +/- 72.4), and IL-6 (234.1 +/- 135.2) in DHCM were significantly increased and only IL-6 was significantly different from HNCM. sFas-L (0.18 +/- 0.08 versus 0.25 +/- 0.05 ng/mL) in HNCM was significantly decreased, and the decrease was marked in DHCM (0.05 +/- 0.02). In HNCM, TNF-alpha was negatively correlated with fractional shortening (r = -0.432, P = 0.0062) or positively with IL-6 (r = 0.665, P < 0.0001), while sFas-L was negatively correlated with IL-6 (r = -0.580, P < 0.0001). DHCM with high sFas had significantly higher cumulative incidences of worsening heart failure. The Fas/Fas-L system and proinflammatory cytokines may play an important role in the status of HCM and its progression to DHCM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876807     DOI: 10.1536/ihj.46.231

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  8 in total

Review 1.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

2.  Profilin-1 promotes the development of hypertension-induced artery remodeling.

Authors:  Yan Wang; Jun Zhang; Haiqing Gao; Shaohua Zhao; Xiang Ji; Xiangju Liu; Beian You; Xiao Li; Jie Qiu
Journal:  J Histochem Cytochem       Date:  2014-01-07       Impact factor: 2.479

3.  Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy.

Authors:  Lu Fang; Andris H Ellims; Anna L Beale; Andrew J Taylor; Andrew Murphy; Anthony M Dart
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 4.  Intervention for apoptosis in cardiomyopathy.

Authors:  Hiroyuki Yaoita; Yukio Maruyama
Journal:  Heart Fail Rev       Date:  2008-06       Impact factor: 4.214

5.  Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy.

Authors:  Johanna Kuusisto; Vesa Kärjä; Petri Sipola; Ivana Kholová; Keijo Peuhkurinen; Pertti Jääskeläinen; Anita Naukkarinen; Seppo Ylä-Herttuala; Kari Punnonen; Markku Laakso
Journal:  Heart       Date:  2012-03-24       Impact factor: 5.994

6.  Bioinformatics analysis of the regulatory lncRNA‑miRNA‑mRNA network and drug prediction in patients with hypertrophic cardiomyopathy.

Authors:  Jiajianghui Li; Zining Wu; Deqiang Zheng; Yue Sun; Sisi Wang; Yuxiang Yan
Journal:  Mol Med Rep       Date:  2019-05-23       Impact factor: 2.952

7.  Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Cats With Hypertrophic Cardiomyopathy.

Authors:  Ryan C Fries; Saki Kadotani; Jonathan P Stack; Leah Kruckman; Gabrielle Wallace
Journal:  Front Vet Sci       Date:  2022-03-14

Review 8.  Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies.

Authors:  Emanuele Monda; Giuseppe Palmiero; Marta Rubino; Federica Verrillo; Federica Amodio; Francesco Di Fraia; Roberta Pacileo; Fabio Fimiani; Augusto Esposito; Annapaola Cirillo; Adelaide Fusco; Elisabetta Moscarella; Giulia Frisso; Maria Giovanna Russo; Giuseppe Pacileo; Paolo Calabrò; Olga Scudiero; Martina Caiazza; Giuseppe Limongelli
Journal:  Int J Mol Sci       Date:  2020-09-04       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.